Drug Company Shares Fall After Death of Ebola Patient in Dallas

CNBC reports that shares of drug of pharmaceutical companies working on Ebola treatments dropped following the death of Thomas Eric Duncan, the first U.S. patient to be diagnosed with the disease.

Duncan was treated with an experimental drug called brincidofovir, made by Chimerix. The company’s shares declined by as much as 13 percent in heavy volume, CNBC reports.

Two Chimerix competitors, Tekmira and BioCryst, saw slight upticks in share price, while Sarepta Therapeutics fell about 2 percent.


Keep me up to date on the latest happenings and all that D Magazine has to offer.